字号·· | 护眼
路透社

辉瑞以最高26亿美元从中国Starna授权CAR-T疗法Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal

点「原文对照」整页切到原文,或双击某段只看那段的原文。

2025年11月6日,中国上海,第八届中国国际进口博览会上,辉瑞公司展台的公司标识。路透社/马克西姆·舍梅托夫/资料图片Logos of Pfizer at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov/File Photo

辉瑞周三表示,已与中国Starna Therapeutics达成独家许可协议,开发三种用于自身免疫性疾病的CAR-T疗法,交易价值最高达26亿美元。

Pfizer said on Wednesday it had struck an exclusive licensing agreement with China's Starna Therapeutics to develop three CAR-T therapies for autoimmune diseases, in a deal worth up to $2.6 billion.

这笔交易标志着这家制药巨头再次押注中国生物科技公司,旨在为2028年重启增长做准备,同时应对专利到期潮以及与新冠相关收入的持续下降。

The deal marks another bet on a Chinese biotech by the pharma major as it seeks to reignite growth by 2028 while preparing for a wave of patent expirations and continued declines in COVID-related revenue.

辉瑞将向Starna支付3.3亿美元的预付款,如果疗法达到开发、监管和销售里程碑,还可能再支付最高23亿美元。这些疗法尚未进入人体试验。Starna还将就任何获批产品的销售获得特许权使用费。协议授予辉瑞在大中华区以外开发和商业化三种早期自身免疫性疾病项目的权利,初始临床试验用药将在其美国设施生产。

体内CAR-T疗法旨在直接在体内对免疫细胞进行基因重编程,使其能够靶向并消除致病免疫细胞。相比之下,传统CAR-T治疗涉及在体外采集并重新编程患者细胞,然后再回输的复杂过程。这笔交易紧随辉瑞5月与信达生物达成的105亿美元协议,以及此前与中国3SBio的交易。

Pfizer will pay Starna $330 million upfront and could pay up to $2.3 billion more if the treatments meet development, regulatory and sales milestones. The therapies have not yet entered human trials Starna would also receive royalties on sales of any approved products The agreement gives Pfizer rights to develop and commercialize three early-stage autoimmune disease programs outside Greater China, with initial clinical trial supplies to be manufactured at its US facilities In vivo CAR-T therapies are designed to genetically reprogram immune cells directly inside the body, allowing them to target and eliminate disease-causing immune cells By contrast, conventional CAR-T treatments involve the complex process of collecting and re-engineering a patient's cells outside the body before reinfusing them The deal follows Pfizer's $10.5 billion agreement with Innovent Biologics in May and an earlier deal with China's 3SBio in 2025

阅读媒体原文 ↗